Symptoms of Women With High-Risk Early-Stage Ovarian Cancer

被引:15
|
作者
Chan, John K.
Tian, Chunqiao
Kesterson, Joshua P.
Monk, Bradley J.
Kapp, Daniel S.
Davidson, Brittany
Robertson, Sharon
Copeland, Larry J.
Walker, Joan L.
Wenham, Robert M.
Casablanca, Yovanni
Spirtos, Nick M.
Tewari, Krishnansu S.
Bell, Jeffrey G.
机构
[1] Sutter Res Inst, Palo Alto Med Fdn, Calif Pacific, Palo Alto, CA USA
[2] Roswell Pk Comprehens Canc Ctr, Clin Trial Dev Div, Biostat & Bioinformat, NRG Oncol, Buffalo, NY USA
[3] Penn State Hershey Med Ctr, Hershey, PA USA
[4] Univ Arizona, Creighton Univ, Arizona Oncol US Oncol Network, Sch Med,St Josephs Hosp,Coll Med, Phoenix, AZ USA
[5] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[6] Duke Univ, Durham, NC USA
[7] Indiana Univ, Indianapolis, IN 46204 USA
[8] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
[9] Oklahoma Univ Hosp, Stephenson Canc Ctr, Oklahoma City, OK USA
[10] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[11] Uniformed Serv Univ Hlth Sci, Walter Reed Natl Mil Med Ctr, Bethesda, MD 20814 USA
[12] Womens Canc Ctr Nevada, Las Vegas, NV USA
[13] Univ Calif Irvine, Irvine, CA USA
[14] Riverside Methodist Hosp, Columbus, OH 43214 USA
基金
美国国家卫生研究院;
关键词
WEARABLE DEVICES; DIAGNOSIS; CARCINOMA; SURVIVAL; INDEX;
D O I
10.1097/AOG.0000000000004642
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To assess the presentation, characteristics, and prognostic significance of symptoms in patients with high-risk early-stage epithelial ovarian cancer. METHODS: A retrospective chart review was performed on all patients enrolled in a phase III clinical trial (GOG 157). All patients had surgically staged, high-risk early-stage epithelial ovarian cancer (stage IA-IB and grade 3, any clear cell, stage IC or II). Chi-square and Kaplan-Meier estimates and Cox proportional hazards models were used for statistical analyses. RESULTS: Of 419 patients evaluated for symptoms, 301 (72%) presented with one or more symptoms, and 118 (28%) were asymptomatic but had a mass found on examination. Forty percent had only one symptom, and 32% had more than one symptom. Among those with at least one symptom, the most common were abdominal and pelvic pain (31%), and increased girth or fullness (26%). Overall, 23% of patients with tumors 10 cm or smaller, 27% of patients with tumors larger than 10 cm to 15 cm, and 46% of patients with tumors larger than 15 cm had multiple symptoms (P<.001). There was no significant difference in presentation of symptoms based on age, stage, or histologic subtype. Symptoms at diagnosis were not associated with recurrence or survival. CONCLUSION: More than 70% of patients with high-risk early-stage, epithelial ovarian cancer present with one or more symptoms, with the most common being abdominal or pelvic pain. The proportion of women with symptoms and the number of symptoms increase with enlarging tumor size.
引用
收藏
页码:157 / 162
页数:6
相关论文
共 50 条
  • [31] Serum screening for detection of high-risk group for early-stage diffuse type gastric cancer in Japanese
    Ito, Masanori
    Yoshihara, Masaharu
    Takata, Shunsuke
    Wada, Yoshihiro
    Matsuo, Taiji
    Boda, Tomoyuki
    Tanaka, Shinji
    Chayama, Kazuaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (03) : 598 - 602
  • [32] Ovarian preservation for premenopausal women with early-stage endometrial cancer: a Chinese retrospective study
    Lyu, Tianjiao
    Guo, Lu
    Chen, Xiaojun
    Jia, Nan
    Gu, Chao
    Zhu, Menghan
    Zhao, Yuqing
    Liu, Xiaoxia
    Feng, Weiwei
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (06) : 2492 - 2498
  • [33] Predictive factors of recurrence in patients with early-stage epithelial ovarian cancer
    Ditto, Antonino
    Maggiore, Umberto Leone Roberti
    Bogani, Giorgio
    Martinelli, Fabio
    Chiappa, Valentina
    Evangelista, Maria Teresa
    Liberale, Viola
    Ferrero, Simone
    Raspagliesi, Francesco
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2019, 145 (01) : 28 - 33
  • [34] Lipid Alterations in Early-Stage High-Grade Serous Ovarian Cancer
    Iurova, M. V.
    Chagovets, V. V.
    Pavlovich, S. V.
    Starodubtseva, N. L.
    Khabas, G. N.
    Chingin, K. S.
    Tokareva, A. O.
    Sukhikh, G. T.
    Frankevich, V. E.
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [35] The Impact of Surgery Delay on Early-Stage Ovarian Cancer
    Zouzoulas, Dimitrios
    Tsolakidis, Dimitrios
    Sofianou, Iliana
    Karalis, Tilemachos
    Aristotelidis, Michalis
    Tzitzis, Panagiotis
    Deligeoroglou, Evangelia
    Topalidou, Maria
    Timotheadou, Eleni
    Grimbizis, Grigoris
    LIFE-BASEL, 2025, 15 (01):
  • [36] A call for prospective studies in early-stage ovarian cancer
    Naik, R.
    Ledermann, J.
    Cross, P. A.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2010, 117 (12) : 1441 - 1443
  • [37] Lymphovascular Space Invasion (LVSI) Is an Isolated Poor Prognostic Factor for Recurrence and Survival Among Women With Intermediate- to High-Risk Early-Stage Endometrioid Endometrial Cancer
    Weinberg, Lori E.
    Kunos, Charles A.
    Zanotti, Kristine M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08) : 1438 - 1445
  • [38] The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study
    Chan, John K.
    Tian, Chunqiao
    Fleming, Gini F.
    Monk, Bradley J.
    Herzog, Thomas J.
    Kapp, Daniel S.
    Bell, Jeffrey
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 301 - 306
  • [39] Survival Impact of Ovarian Preservation on Women With Early-Stage Endometrial Cancer A Systematic Review and Meta-analysis
    Gu, Haifeng
    Li, Jundong
    Gu, Yangkui
    Tu, Hua
    Zhou, Yun
    Liu, Jihong
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (01) : 77 - 84
  • [40] Parametrial involvement in women with low-risk, early-stage cervical cancer
    Vanichtantikul, A.
    Tantbirojn, P.
    Manchana, T.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (05)